#Israel #Caesarea #IceCure Medical #Cryoablation #ProSense

IceCure Medical's Breakthrough in Cryoablation Technology

In a recent development that could significantly change the landscape for breast fibroadenoma treatment, IceCure Medical Ltd. has announced the publication of an independent study demonstrating the effectiveness of their ProSense® cryoablation system. This peer-reviewed study, featured in the journal PLOS One, indicates a groundbreaking approach to managing non-cancerous breast tumors, providing new hope for women facing this common condition.

Understanding Fibroadenomas

Fibroadenomas are benign tumors that commonly appear in breast tissue, often discovered through core needle biopsy. According to estimates from the Cleveland Clinic, up to 10% of women will develop at least one fibroadenoma in their lifetime. The traditional treatment for this condition has been surgical excision, particularly for larger tumors or those causing discomfort.

Given the estimated 63,000 cases of fibroadenoma excision performed annually in the U.S., there is a pressing need for effective alternative treatments that minimize patient recovery time and scarring. IceCure Medical’s ProSense® offers a promising solution by leveraging cryoablation technology—a minimally invasive method that freezes and destroys tumors without the need for traditional surgery.

Study Highlights and Findings

The recent study conducted at the Premier Med Healthcare, Training, and Research Institute in Hungary explored the effectiveness of cryoablation using the ProSense® system for treating larger fibroadenomas. Led by Dr. Teodora Filipov and Dr. Pál Ákos Deák, the research assessed the outcomes of patients treated with this innovative technology. Findings revealed impressive results, showcasing a median volume reduction of 80.6% at six months post-treatment, escalating to a remarkable 92.9% after one year.

What set this study apart was its focus on larger fibroadenomas and the use of multiple cryoprobe relocations, an approach that was not extensively studied prior. Dr. Filipov emphasized that this research lays the groundwork for a shift in clinical practice guidelines, particularly regarding the treatment of non-cancerous breast tumors.

Patient Benefits and Future Implications

Eyal Shamir, CEO of IceCure Medical, articulated the significance of these findings, suggesting that they may reshape treatment guidelines established by medical societies such as the American Society of Breast Surgeons. The benefits of cryoablation, as noted in the study, include not only a significant reduction in tumor size but also an improved safety profile compared to traditional surgical methods.

The ProSense® system stands out because it can be utilized in an outpatient setting, providing a faster recovery for patients. The system’s design incorporates liquid nitrogen to create an extensive lethal zone for optimal tumor destruction, reducing pain and minimizing associated surgical risks.

This innovative method not only empowers patients but also provides physicians with a reliable alternative for managing benign breast tumors. It underscores a critical advancement in the longstanding quest for less invasive treatment options that not only prioritize patient safety but also enhance overall treatment efficacy.

The Road Ahead for IceCure Medical

Looking ahead, IceCure Medical aims to continue expanding the clinical applications of its ProSense® technology. With FDA clearance already achieved for the treatment of fibroadenomas and a commitment to research and development, the company is well-positioned to redefine how benign tumors are managed in clinical practice.

As ongoing research reinforces the safety and effectiveness of ProSense® cryoablation, the hope is that both medical professionals and patients will increasingly turn to this technology as a preferred method for managing breast fibroadenomas. The future looks promising, not only for IceCure Medical but for patients seeking effective treatment solutions for this common medical condition.